Last Updated 11 December 2014
The HIV therapy market is highly dynamic. Over the past ten years, many effective antiretroviral therapies (ARTs) have been introduced, prompting changes in treatment guidelines and clinical practices. Over the next ten years, the HIV market will increase and then decline as generic erosion of preferred agents constrains market growth driven by uptake of newer therapies. In general, current and emerging brands that simplify treatment regimens through fixed-dose combinations (FDCs) or single-tablet regimens (STRs) will find favorable uptake. Notably, market share for stand-alone integrase inhibitors and integrase inhibitor-based FDCs will expand based on their higher efficacy, better safety, and greater barrier to drug resistance, which are hallmarks of this class of ART.